Advanced Therapy Medicinal Products Market size is anticipated to cross USD 31,706.8 Million by the end of 2031, growing at a CAGR of 13.4% during the forecast period, i.e., 2021-2031. In the year 2021, the industry size of advanced therapy medicinal products was USD 9,097.5 Million. The growth of the market can be attributed to the increased prevalence of the genetic disorder. Drugs used in gene therapy are advanced therapy medicinal products that contain genes that have therapeutic, preventative, or diagnostic effects. Recombinant genes are inserted into the body to cure a number of illnesses, such as cancer, genetic problems, and chronic diseases. For instance, all over the world around 300 million people are living with a rare disease and it affects nearly 4% to 6% of the total world population.
In addition to these, factors that are believed to fuel the growth of the advanced therapy medicinal products market include higher adoption of gene therapy. Gene therapy is known to be one of the advanced therapy medicinal products. The therapy is used to treat the underlying genetic disorder by correcting the faulty gene in the body. In one study, 93 percent of respondents supported the use of gene therapy to treat Leber congenital amaurosis, an inherited form of blindness, while just 35 percent said it was certainly okay to use it to improve memory. Furthermore, advanced therapy medicinal products are used to replace or restore dopamine transmission in various parts of the nervous system. Therefore, increased cases of neurological ailment are anticipated the higher projection of the advanced therapy medicinal products market. According to the Pan American Health Organization’s 2019 statistics, around 7.5 million people are living with a neurological disorder and 533,172 deaths are due to the neurological condition.
Growth Drivers
An illness characterized by one or more anomalies in the genome is referred to as a genetic condition. Advanced therapy medicinal products are one of the most effective ways to treat genetic disorder. According to the World Health Organization, around 2%–5% of all live births are affected by genetic illnesses and congenital anomalies, which can also be responsible for up to 50% of infant fatalities and 30% of pediatric hospital admissions in developed nations.
Neurological disorder has become more prevalent among the people. People are getting affected by dementia, Alzheimer’s disease and others. As per the statistics of the United Nations, every year around 6.8 million people die of maladies, moreover, every 1 in 6th person is suffering from a neurological disorder.
Gene therapy is used to replace the faulty gene and add the fit gene to the body. this procedure helps in fighting various diseases, such as cancer, AIDS, diabetes, and others. The number of people to be treated by gene therapy is estimated to be around 1 million from the year 2020 to 2034.
With the increase in investment in the market, the research and development of advanced therapy medicinal products are also rising. In 202o, around USD 360 million were invested in cell therapy alone, and by 2021 it grew to nearly USD 70 billion.
By the reports of the World Economic Forum, currently, there are more than 2000 advanced therapies in the development stage, and they are expected to treat larger pool of diseases.
Challenges
|
Base Year |
2021 |
|
Forecast Year |
2021-2031 |
|
CAGR |
13.4% |
|
Base Year Market Size (2021) |
USD 9,097.5 Million |
|
Forecast Year Market Size (2031) |
USD 31,706.8 Million |
|
Regional Scope |
|
Disease (Oncology, Genetic Disorder, CNS, Dermatology)
The global advanced therapy medicinal products market is segmented and analyzed for demand and supply by disease into oncology, genetic disorder, CNS, dermatology, and others. Out of all, the dermatology segment is to garner the highest revenue of USD 9,498 million at the end of 2031, by growing at a CAGR of 12.5% over the forecast period. Moreover, in 2020, the segment garnered a revenue of USD 2,961.7 million. The segment growth is expected on the back of rising cases of skin problems and cancer in the world. According to the World Health Organization, currently, 132,000 cases of melanoma and 2 to 3 million cases of non-melanoma skin cancer are reported annually worldwide. Skin cancer accounts for one in three cancer diagnoses, and one in five Americans will have it at some point in their lives.
Product (CAR-T Therapy, Gene Therapy, Cell Therapy, Tissue Engineered Product)
The global advanced therapy medicinal products market is also segmented and analyzed for demand and supply by product into CAR-T therapy, gene therapy, cell therapy, and tissue-engineered product. Amongst these four segments, the gene therapy segment is expected to garner a market revenue of USD 11,674.9 million at the end of 2031 by growing at a CAGR of 13.8% over the forecast period. Moreover, the segment generated a revenue of USD 3,241.9 million in 2021. The segment growth is expected on the back of a higher number of people in need of gene therapy and growing clinical trials of gene therapy. By 2034, gene therapies could be used to treat more than 1 million Americans. Furthermore, in 2022, around 1221 cell and gene therapies are under active clinical trials, moreover, out of them nearly 324 clinical trials are in the phase of 1/1b.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Disease |
|
|
By End User |
|
North American Market Forecast
The North America advanced therapy medicinal products market, amongst the market in all the other regions, is projected to hold the largest market share of USD 14,020.7 million by the end of 2031 by growing at a CAGR of 13.1% over the forecast period. The region generated the revenue of USD 4,150.3 million in 2021. The market growth in North America is attributed to higher cases of cancer and neurological disorder followed by investment by private companies for the development of advanced therapy medicinal products. In 2022, around 600,000 deaths are attributed to the cancer cases and nearly 2 million new cases of cancer were diagnosed in the United States. Furthermore, in 2019, Pfizer Inc. a leading U.S. based pharmaceutical company announced the investment of USD 500 million to expand the gene therapy manufacturing unit in Sanford, North Carolina.
Novartis AG in collaboration with Medicines for Malaria Venture announced the entry of novel ganaplacide/lumenfantrine-SDF into the phase 3 study. This novel is a combination to treat uncomplicated malaria in both adults and children.
Takeda Pharmaceutical Company Limited announced the collaboration and licensing agreement with Zedira and Dr.Falk Pharma for the development of first in class Celiac disease therapy. It is a serious autoimmune disease, in which intake of gluten damages the small intestine.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?